Bio-Techne beats Q2 earnings and revenue estimates, stock price rises in premarket.

From Zacks Investment Research: 2025-02-05 15:12:14

Bio-Techne (TECH) reported second-quarter fiscal 2025 adjusted earnings per share of 42 cents, exceeding the Zacks Consensus Estimate by 10.5%. GAAP EPS was 22 cents. Following the earnings announcement, shares of TECH rose 4.8% in pre-market trading. Revenues totaled $297.0 million, up 9% year over year. Bio-Techne’s gross margin expanded to 65.3%. Operating margin expanded to 16%. The company ended the quarter with cash and equivalents of $177.5 million. Bio-Techne’s management is optimistic about the results. TECH currently carries a Zacks Rank #4 (Sell).

Other better-ranked stocks in the medical space are Quest Diagnostics (DGX), ResMed (RMD), and Cardinal Health (CAH). Quest Diagnostics reported fourth-quarter 2024 adjusted EPS of $2.23, beating estimates. ResMed posted second-quarter fiscal 2025 adjusted EPS of $2.43, also surpassing estimates. Cardinal Health reported second-quarter fiscal 2025 adjusted EPS of $1.93, outpacing estimates. DGX has a Zacks Rank #2 (Buy), RMD has a Zacks Rank #2, and CAH has a Zacks Rank #2.



Read more at Zacks Investment Research: Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket – February 5, 2025